USPTO serial 97839291
BIOSPRING
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 2, 2024
- Examiner
- PARK, JENNY K
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BIOSPRING?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
BioSpring Gesellschaft für Biotechnologie mbH
Franfurt, DE
Other trademarks owned by BioSpring Gesellschaft für Biotechnologie mbH
BioSpring Gesellschaft für Biotechnologie mbH
Franfurt, DE
Other trademarks owned by BioSpring Gesellschaft für Biotechnologie mbH
BioSpring Gesellschaft für Biotechnologie mbH
Franfurt, DE
Other trademarks owned by BioSpring Gesellschaft für Biotechnologie mbH
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Julie A. Katz
Julie A. Katz JULIE A. KATZ1711 N HERMITAGE AVECHICAGO, IL 60622United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | oligonucleotides for use in the manufacture of pharmaceuticals; oligopeptides for industrial use; peptide substrates for scientific use; peptides for use in industry and science; peptides for use in research and the manufacture of reagents, diagnostic reagents for science and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; phosphoproteins; proteins for use in industry and science; reagents for research purposes; reagents for scientific use; nucleic acid for diagnostic research; nucleic acid for diagnostic manufacturing | ACTIVE | Apr 30, 2017 |
| 005 | nucleic acid reagents, agents, preparations and substances for medical purposes; nucleic acid sequences for medical and veterinary use; oligonucleotides for diagnostic purposes; oligonucleotides for medical diagnostic purposes; oligonucleotides for medical use; oligonucleotides for pharmaceutical purposes; pharmaceutical preparations against genetic diseases; pharmaceutical preparations against metabolic diseases; pharmaceutical preparations against neurological diseases; pharmaceutical preparations for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, respiratory diseases, cancer, allergies, gynecological diseases, rheumatic diseases, urological diseases, gastroenterological diseases, infectious diseases, eye disease, dermatological diseases, autoimmune diseases, blood diseases, genital diseases, endocrine diseases, intestinal diseases, internal medicine diseases; pharmaceutical preparations for wound healing; reagents for medical purposes; reagents for medical use; reagents for use in medical genetic testing; reagents for use in veterinary genetic testing; tumor suppressing agents | ACTIVE | Apr 30, 2017 |
| 040 | biochemical contract manufacturing services; chemical synthesis services, namely, custom synthesis of chemicals for others; custom manufacture of biopharmaceuticals; custom manufacture of pharmaceuticals; custom manufacturing of oligonucleotides; custom modification of antibody; custom modification of protein; development services, namely, design and development of manufacturing processes for others in the field of oligonucleotides; manufacturing, namely, contract manufacturing in the field of oligonucleotides; processing of biopharmaceutical materials for others; processing of chemical reagents; processing of chemicals; processing of medicinal materials; processing of oligonucleotides; processing of peptides; processing of proteins; technical and scientific services, namely, providing technical information in the field of pharmaceutical manufacturing | ACTIVE | Apr 30, 2017 |
| 042 | scientific analysis services for the identification and physical characterization of chemical molecules; scientific and technical services, namely, scientific analysis of industrial installations; scientific and technological services, namely, applied scientific research and development services, namely, conception of development or commercial batches for third parties in the fields of pharmaceuticals and chemicals; scientific and technological services, namely, consulting and assistance in the research and development of chemicals and pharmaceuticals, including experimental and production processes and installations; scientific and technological services, namely, consulting and assistance in the research and development of pharmaceuticals; scientific development services in the field of biochemistry; scientific laboratory services; scientific research and development services for chemicals for the products of third parties, namely, the scientific and technical development of synthetic processes in the field of chemistry and biochemistry; scientific research and development services in the field of pharmaceuticals; scientific research and scientific and technical development in the field of pharmaceutical, chemical, agrochemical and industrial processes; scientific research services, namely, nucleic acid analysis; scientific research services, namely, oligonucleotide analysis; scientific services, namely, scientific analysis allowing the identification and physical characterization of chemical molecules; scientific services, namely, scientific research and industrial analysis in the field of pharmaceuticals, chemicals, and agrochemical and industrial processes; scientific study and research in the area of industrial quality; development of methods of analysis for chemical and pharmaceutical products and bio-organics; scientific study and research services in the field of industrial safety | ACTIVE | Apr 30, 2017 |
| 044 | nucleic acid analysis for medical diagnostic and treatment purposes; oligonucleotide analysis for medical diagnostic and treatment purposes | ACTIVE | Apr 30, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioSpring Gesellschaft für Biotechnologie mbH
- Other trademarks owned by BioSpring Gesellschaft für Biotechnologie mbH
- Other trademarks owned by BioSpring Gesellschaft für Biotechnologie mbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BIOSPRING
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 26, 2024 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Oct 24, 2024 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Oct 23, 2024 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Oct 23, 2024 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Oct 22, 2024 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Sep 17, 2024 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Sep 10, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 12, 2024 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Apr 2, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 2, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 14, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 14, 2023 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| Dec 13, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 13, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 13, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 13, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 13, 2023 | IUAA | USE AMENDMENT ACCEPTED | — |
| Dec 11, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 25, 2023 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Aug 25, 2023 | IUAF | USE AMENDMENT FILED | — |
| Aug 24, 2023 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Apr 4, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 17, 2023 | NWAP | NEW APPLICATION ENTERED | — |